Compare ServiceNow Inc (NOW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs BIO-TECHNE Corp — how do they compare? ServiceNow Inc trades at $126.89 (market cap $129.11B), while BIO-TECHNE Corp trades at $72.16 (market cap $11.24B). The key difference: ServiceNow Inc is far larger — about 11.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals.
| NOW | TECH | |
|---|---|---|
Market Cap | $129.11B | $11.24B |
Sector | Technology | Health |
52-Week High | $192.23 | $72.29 |
52-Week Low | $83.00 | $43.31 |
Enterprise Value | $132.90B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $124.88, up 6.42% in the last 24 hours, reflecting strong momentum near its pivot point of $124. The stock shows bullish technical signals with moving averages supporting an uptrend, though RSI levels indicate potential overbought conditions. Fundamentally, revenue grew to $13.28 billion in 2025 with a net income margin of 11.34%, but high valuation ratios like a P/E of 78.05 suggest premium pricing. Recent news highlights AI-driven growth opportunities and conference presentations boosting investor confidence.
The outlook for NOW is positive with an analyst consensus price target of $138.26, implying ~11% upside. Key opportunities include AI integration and revenue expansion, but risks involve elevated valuations and competitive pressures. Earnings consistency remains crucial, with Q3 2026 results anticipated to validate growth trajectory.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
